Pharmaceutical

Risk adjusted net present value: What is the current valuation of Pfizer’s PF-07275315?

PF-07275315 is a monoclonal antibody commercialized by Pfizer, with a leading Phase II program in Atopic Dermatitis (Atopic Eczema).

Apr 17, 2024 - 00:00
PF-07275315 is a monoclonal antibody commercialized by Pfizer, with a leading Phase II program in Atopic Dermatitis (Atopic Eczema).
Read the original article

Tags:

Previous Article

Risk adjusted net present value: What is the current valuation of Enliven Therap...

Next Article

Risk adjusted net present value: What is the current valuation of Eli Lilly and ...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Medicare may plan to negotiate drug prices, but some states are taking their own steps to lower costs

STAT+: Medicare may plan to negotiate drug prices, but ...

Oct 12, 2023

StromaForte by Swedish StromaBio for Ageing: Likelihood...

Nov 6, 2023

STAT+: Top Senate Republican signals interest in site-neutral reform for hospitals

STAT+: Top Senate Republican signals interest in site-n...

Jun 8, 2023